Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.
Int J Mol Sci
December 2024
Department of Hematology and Oncology, University Medical Center Schleswig-Holstein (UKSH), University Cancer Center Schleswig-Holstein (UCCSH), Campus Lübeck, 23538 Lübeck, Germany.
The complex and heterogeneous genomic landscape of multiple myeloma (MM) and many of its clinical and prognostic implications remains to be understood. In other cancers, such as breast cancer, using whole-exome sequencing (WES) and molecular signatures in clinical practice has revolutionized classification, prognostic prediction, and patient management. However, such integration is still in its early stages in MM.
View Article and Find Full Text PDFMultiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.
Int J Mol Sci
December 2024
Laboratory of Molecular Genetics, Department of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Multiple myeloma (MM) is characterized by the uncontrolled proliferation of monoclonal plasma cells and accounts for approximately 10% of all hematologic malignancies. The clinical outcomes of MM can exhibit considerable variability. Variability in both the genetic and epigenetic characteristics of MM undeniably contributes to tumor dynamics.
View Article and Find Full Text PDFTime to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation.
Hematology
December 2025
Department of Hematology, The First People's Hospital of Changzhou, Changzhou Medical Center, Nanjing Medical University, Changzhou, People's Republic of China.
Objectives: Currently, there is limited understanding regarding the prognostic significance of time to progression (TTP) after first remission in multiple myeloma (MM).
Methods: We conducted a retrospective analysis of clinical data from 209 patients with MM. These patients were categorized into ≤ 6 months, ≤ 12 months, ≤ 24 months, > 24 months, 6-12 months, and 12-24 months subgroups based on TTP.
[Expression and Clinical Significance of in Multiple Myeloma Cells].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, Anhui Province, China.
Objective: To investigate the expression of in newly diagnosed multiple myeloma (MM) and its correlation with clinical features and prognosis.
Methods: 115 MM patients diagnosed and treated in the Department of Hematology, the First Affiliated Hospital of Bengbu Medical University from January 2013 to January 2017 and 115 non-tumor controls were enrolled in this study. Clinical characteristics, pathological data and therapeutic responses of the patients were collected.
[Prognostic Value and Threshold Effect of Serum C3, C4 in Patients with Multiple Myeloma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Clinical Laboratory, Suqian First People's Hospital, Suqian 223800, Jiangsu Province, China.
Objective: To analyze the prognostic value and threshold effect of serum C3, C4 in patients with multiple myeloma (MM).
Methods: The clinical data of 146 patients with MM who visited Suqian First People's Hospital from October 2016 to October 2019 were collected. The patients were divided into deceased group (42 cases) and survival group (104 cases) according to their prognosis and survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!